Clinical Trial Update: Evaluate the Safety Profile and Ability of TW1025 Oral Solution to Decrease Fatigue [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating TW1025 oral solution for safety and reduction of fatigue in patients with metastatic breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• TW1025

Snippet

Sponsor: Meriyana Bio Inc. | Conditions: Metastatic Breast Cancer, Fatigue | Phase 2 | Status: TERMINATED